Back to top

Analyst Blog

PDL BioPharma Inc. (PDLI - Analyst Report) posted third-quarter earnings of 32 cents per share, in line with the Zacks Consensus Estimate but above the year-ago figure of 28 cents. The year-over-year increase was attributable to higher revenues.

PDL BioPharma generated third-quarter 2012 revenues of $85.2 million, up 1.7% year over year. Revenues were slightly above the guidance of $85 million announced by the company in September 2012. Revenues narrowly missed the Zacks Consensus Estimate of $86 million.

Quarter in Detail

PDL BioPharma derived revenues for the third quarter of 2012 solely from royalties. PDL BioPharma receives royalties on worldwide net sales of Roche Holdings Ltd.'s (RHHBY - Analyst Report) Avastin and Herceptin; Roche/ Novartis’ (NVS - Analyst Report) Lucentis and Xolair; and Elan Corporation/Biogen Idec’s (ELN / Tysabri.

Increased royalties on sales of Avastin, Lucentis and Xolair drove third quarter 2012 royalties.

Effective from the second quarter of 2011, PDL BioPharma started paying back a portion of the royalties it receives on Lucentis sales outside the US to Novartis. The payment is made in accordance with a settlement agreement, which the companies had entered into in February 2011. The third-quarter 2012 revenue is net of this payment.

General and administrative (G&A) expenses were $5.6 million in the reported quarter, up approximately 42.6% due to the company’s efforts to obtain new royalty assets, legal expenses and compensation related expenses.

On September 14, 2012, PDL BioPharma paid the third quarterly dividend of 15 cents per share.

The company is expected to provide revenue guidance for the fourth quarter of 2012 in December 2012.

Our Recommendation

We currently have a Neutral recommendation on PDL BioPharma. The stock carries a Zacks #5 Rank (Strong Sell rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%